Denosumab: The Better Option for Bone Metastases in NSCLC?Denosumab: The Better Option for Bone Metastases in NSCLC?

Dr. Jack West discusses data indicating that denosumab is superior to zoledronic acid in reducing skeletal complications and increasing overall survival in lung cancer patients with bone metastases. Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news